25 results on '"Velders, Gerjo A."'
Search Results
2. A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
3. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
4. Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
5. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
6. Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.
7. Improving the identification of frail elderly newly diagnosed multiple myeloma patients
8. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
9. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
10. P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
11. First-Line Treatment of Waldenström’s Macroglobulinaemia: Considerations Based on the Dutch National Guideline
12. Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study
13. Serpina1 Is a Potent Inhibitor of IL-8-Induced Hematopoietic Stem Cell Mobilization
14. P-116 The simplified frailty index (S-FI) identifies a less vulnerable population of frail patients than patients who are defined frail using the International Myeloma working Group Frailty index (IMWG-FI)
15. Involvement of Proteases in Cytokine-Induced Hematopoietic Stem Cell Mobilization
16. Reduced stem cell mobilization in mice receiving antibiotic modulation of the intestinal flora: involvement of endotoxins as cofactors in mobilization
17. Biology of IL-8-Induced Stem Cell Mobilization
18. First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment
19. Enhancement of G-CSF–induced stem cell mobilization by antibodies against the β2 integrins LFA-1 and Mac-1
20. Polycytemie bij een patiënte met een uterusmyoom
21. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program
22. Alpha-1 Antitrypsin Is a Potent Inhibitor of Cytokine-Induced Hematopoietic Stem Cell Mobilization.
23. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
24. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.
25. Hematopoietic stem and progenitor cells are differentially mobilized depending on the duration of Flt3-ligand administration.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.